<DOC>
	<DOCNO>NCT02112994</DOCNO>
	<brief_summary>This study evaluate safety efficacy sebelipase alfa broad population patient lysosomal acid lipase deficiency ( LALD ) .</brief_summary>
	<brief_title>Safety Efficacy Study Sebelipase Alfa Patients With Lysosomal Acid Lipase Deficiency</brief_title>
	<detailed_description>The primary objective study evaluate safety intravenous infusion sebelipase alfa broad population LALD patient previously study . Such patient may exclude enrollment study LALD age , disease progression , previous treatment hematopoietic stem cell liver transplantation , less common disease manifestation , disease characteristic would preclude participation placebo-controlled study . This open-label study include infant &gt; 8 month , child adult . Eligible patient receive sebelipase alfa dose 1 mg/kg every week .</detailed_description>
	<mesh_term>Wolman Disease</mesh_term>
	<criteria>Key 1 . Patient &gt; 8 month age time dose . 2 . Confirmation LALD diagnosis determine central lab . 3 . Patients &gt; 8 month &lt; 4 year age Screening least 1 follow document clinical manifestation LALD : Dyslipidemia Elevated transaminase ( ALT ≥1.5x ULN ) Impaired growth Suspected malabsorption Other clinical manifestation LALD 4 . Patients ≥ 4 year age Screening least 1 follow document clinical manifestation LALD : Evidence advance liver disease Histologically confirm disease recurrence patient past liver hematopoietic transplant Persistent dyslipidemia Suspected malabsorption Other clinical manifestation LALD Key 1 . Patient known cause active liver disease LALD adequately treat . 2 . Patient receive hematopoietic stem cell liver transplant &lt; 2 year time dose . 3 . Patient comorbidities complication due LALD irreversible associate high mortality risk within 6 month , would interfere study compliance data interpretation .</criteria>
	<gender>All</gender>
	<minimum_age>8 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Enzyme Replacement Therapy ( ERT )</keyword>
	<keyword>Lysosomal Storage Disease</keyword>
	<keyword>Late Onset Lysosomal Acid Lipase ( LAL ) Deficiency</keyword>
	<keyword>Acid cholesteryl ester hydrolase deficiency , type 2</keyword>
	<keyword>Acid lipase disease</keyword>
	<keyword>Cholesterol ester hydrolase deficiency</keyword>
	<keyword>LAL Deficiency</keyword>
	<keyword>LIPA Deficiency</keyword>
	<keyword>Wolman disease</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Cholesterol Ester Storage Disease</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Lipidoses</keyword>
	<keyword>Lipid Metabolism , Inborn Errors</keyword>
	<keyword>Metabolism , Inborn Errors</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Lysosomal Storage Diseases</keyword>
	<keyword>Lipid Metabolism Disorders</keyword>
	<keyword>Infant , Newborn , Diseases</keyword>
</DOC>